Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148875 | 0.87 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL149936 | 0.85 | GPR119 (0.34) | GPR119KCNH2MCHR1SIGMAR1 | |
| SCHEMBL149798 | 0.85 | GPR119 (0.43) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL120059 | 0.79 | GPR119 (0.47) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL149751 | 0.78 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL152138 | 0.78 | GPR119 (0.33) | GPR119KCNH2SIGMAR1 | |
| SCHEMBL149154 | 0.75 | GPR119 (0.43) | GPR119KCNH2 | |
| SCHEMBL148491 | 0.74 | GPR119 (0.42) | GPR119KCNH2 | |
| SCHEMBL150998 | 0.72 | GPR119 (0.48) | GPR119KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL1720991 | 0.72 | GPR119 (0.48) | GPR119KCNH2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | claimed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | GPR119 1/4885KCNH2 2010/4885CHRM2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.